INSUFICIENCIA CARDIACA
Insuf Card 2016;11 (3): 115-121
Pulmonary arterial Hypertension in adult congenital heart disease
Impact and outcome
Data from the GUTI-GUCH Registry
Claudio Gabriel Moros, Marisa Pacheco Otero, Gianina Faliva, María del Carmen Rubio, Mariana López Daneri, Isabel Torres, Inés Abella, Álvaro Sosa Liprandi, Liliana Noemí Nicolosi, María Grippo
Introduction
Adult congenital heart disease (ACHD) is one of the fastest growing cardiology subgroups in recent years. Due to early diagnosis and advances in surgical and endovascular treatment.
It’s estimated that 85 – 90% of patients with congenital heart disease will reach adulthood. The survival of these patients generates complications and sequelae that result in a higher rate of hospitalizations and more surgeries, amid other complications.
It is estimated that 5 to 10% of patients with ACHD will develop pulmonary hypertension (PH) during its evolution, being currently the most frequent cause of pulmonary hypertension (PAH) after connective tissue diseases5,6. Its appearance is related to a worse prognosis for the patient.
The purpose of the present study was to analyze the epidemiological characteristics, clinical and pharmaceutical treatments of patients with PAH and their consequences on survival.
